Liraglutide May Increase Bone Strength, Study Shows
January 15, 2020
The GLP-1 receptor agonist liraglutide used to treat patients with type 2 diabetes (T2D) for 26 weeks had no impact on bone resorption, even though subjects lost weight.
Grace Halsey
US Diabetes Treatment is Missing the Mark
September 9, 2019
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
Diabetes Drugs and CV Protection: An 8-question Quiz
January 8, 2019
How well do you know your CV outcomes trial data for novel type 2 diabetes drugs? Your answers to these 8 questions will tell.
Do You Speak DPP-4I?
March 25, 2015
There are 10 FDA-approved DPP-4 inhibitors--single agents and combination products. Do you speak their language? Find out with these 5 questions.
Diabetes Drug Quiz: Do You Know Your Generics vs Trades?
March 18, 2015
Trade names often mask the essential nature of a medication, but some of the new agents that treat type 2 diabetes take it to a new level. Here, 5 chances to see what you know.
10 New FDA-Approved Endocrinology Drugs
February 27, 2015
Since June of 2014, the US FDA has approved a number of drugs for a variety of endocrine-related diseases. Here are 10 of them.
Lead With Weight Loss, Say New Endo Society Guidelines
January 27, 2015
The new guidelines signal a shift toward aggressive treatment for obesity as a primary disease and following with treatment for comorbidites that do not respond to weight loss.
SGLT2 Inhibitors: Basic Training Quiz
October 24, 2014
The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.
SGLT2 Inhibitors: 4 Points on Efficacy, Safety You Need to Know
August 19, 2014
Studies looking at add-on treatment with SGLT2 inhibitors show their effects on glycemic control to be roughly additive. Here, a concise look at clinical trial results plus guidance on renal dose adjustment.
SGLT2 Inhibitors: 5 Things You Should Know
August 7, 2014
Empagliflozin is the third sodium-glucose cotransporter 2 inhibitor approved for use in the US. There is a lot to learn about this new class. Here, 5 of the many things you need to know.
